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Abstract
The ISRCTN register has been operational for the past 8 years and is approaching
10,000 trial records. It complies with international guidelines and pools its data in
the International Trial Search Portal initiated by the World Health Organisation.
Through its ongoing collaboration with the Department of Health in England,
the register has been able to participate in a national initiative aiming to bring
clinical trials to the attention of a wider public with the objective of maximising
participation. As part of BioMed Central, the register provides the ﬁrst step in the
concept of threaded publications, enabling the tracking of clinical research studies
from inception and the linking of all resulting publications including the raw data
where this is available.
Introduction
The ISRCTN Register administered by Current Controlled
Trials (CCT) has been in existence for over 8 years and
is one of the established public trial registers vetted by the
InternationalCommitteeofMedicalJournalEditors(ICMJE)
and pooled in the World Health Organization (WHO) trials
search platform (1).
The register has always enjoyed a close collaboration with
UK-based organisations including the Department of Health
in England. However, its remit remains international and it
is open to all areas of healthcare and all study designs in
all countries, for trialists who wish to declare the existence
of their research, in line with international recommendations
andattherequestofagrowingnumberofscientiﬁcjournals.
Achievements & trends
In response to the growing body of opinion in favor of
prospective registration of randomized trials, the Science
Navigation Group launched the CCT website in 1998. The
aim was to facilitate the exchange of information about ran-
domizedtrialworldwideandtopublishanincreasingnumber
oftrialsprotocolsandtrialresultsviaitspublishingbusiness,
BioMed Central (2).
CCT initially offered the metaRegister of Controlled Tri-
als (mRCT), a platform bringing together different sources
of trial information, allowing those providers to customize
the presentation of their research and helping users to search
those sources in a single environment. In 2003, acknowledg-
ing the fact that the same trial could be present in several
registers pooled in the metaRegister (for example a regis-
ter representing a funding body overlapping with another
register representing a disease area), CCT started the IS-
RCTN (International Randomized Controlled Trial Number)
scheme to allocate a unique trial ID to a trial against a basic
set of trial information. The aim was for the trial ID to be
quoted on all resulting publications.
In 2006, the PubMed LinkOut system was enabled to rec-
ognize trial IDs. When they are quoted in the abstract of an
article, those trials IDs are stored in the PubMed secondary
ID ﬁeld and a banner of the trial register (where all the trial
information isheld)is displayedatthetopoftherecord.This
allows users to go to the original ISRCTN trial registration
details (3).
Over the years, the ISRCTN dataset has been expanded
in line with international guidelines to cater for the needs
of the scientiﬁc community and the general public. It also
includes information on ethics approval, trial end date, pa-
tient information sheet, trial website, as well as the WHO
minimum data set (4). The register also seeks to keep abreast
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Table 1 Growth in the number of trials in the ISRCTN
Number of trials Cumulative Annual
Year added in year total increase
2000 145 145 -
2001 187 332 129%
2002 302 634 91%
2003 729 1363 115%
2004 1065 2428 78%
2005 1493 3921 61%
2006 1304 5225 33%
2007 1220 6445 23%
2008 908 7353 14%
2009 836 8189 11%
2010 1146 9335 14%
of future requirements, such as the inclusion of basic trial
results. In considering the trends over time discussed below,
it is important to keep in mind the caveat that public reg-
istration (deﬁned as voluntary declaration of the existence
of a piece of research, to comply with guidelines from the
research community or funding bodies) is not compulsory.
As a result, an increase or decrease of registration will reﬂect
the amount of focus put on the matter, the funding made
available for public registration, or both. It cannot be used
to indicate that there have been more or fewer trials at any
particular time.
Within the UK, the ISRCTN register is not the result of
national legislation and is not supported by grants or govern-
mental budgets. From 2003, an administrative fee has been
charged for assigning ISRCTNs and hosting trial records
on a website that users can access free and without login.
This is in line with the open access journal publishing model
developed by CCT’s sister company, the Open Access pub-
lisher BioMed Central, where authors pay an Article Pro-
cessing Charge which covers the cost of the publication of
their research article, so that the research can be made freely
available to all.
The requirement for trial registration in publicly avail-
able registers gained momentum in 2005 with declarations
fromtheICMJE(5).Toensurecompliancewithinternational
guidelines, ISRCTN registration activities were also handed
over to a not-for-proﬁt organization ISRCTN.org.
The ISRCTN register proactively contacts trialists to up-
date their data, especially regarding publications, and also
processes any requests for updates that come from trialists.
ISRCTN records are never removed from the ISRCTN, en-
suring that research that is not published is still listed, re-
ducing publication bias and making sure those trials are not
missed by systematic reviewers (6).
As of June 2011, the ISRCTN Register has the following
features:
 Over 9700 records (7) (Tables 1 and 2)
Table 2 Proportion of trials in ISRCTN that are from the UK
Total ISRCTNs UK related % of UK trials
added trials in ISRCTN database
2000 145 133 92%
2001 187 177 95%
2002 302 233 77%
2003 729 679 93%
2004 1,065 923 87%
2005 1,493 648 43%
2006 1,304 547 42%
2007 1,220 496 41%
2008 908 370 41%
2009 836 360 43%
2010 1,146 610 53%
 Fromover90%intheearlyyears,theUKnowcontributes
fewerthan55%ofallthetrialsregistered.Theregisterhas
always been positioned as open to registrations from all
countries. The proportion of non-UK trials has increased
as the existence of the ISRCTN register has become more
widely known internationally and the register has been
offering a reliable registration service for trialists who are
based in countries which may not yet have a local register
or who need to comply with international regulations and
journals’ recommendations. Countries with an increased
research output such as China, Brazil and India are rep-
resented in the top 20 countries (Table 3) but it has to
be noted that these countries have also been developing
their own trial registers and more and more registers are
becoming data providers to the WHO search portal (8).
 Medical journals very much focus on trials of interven-
tions and that is reﬂected in the low number of obser-
vational trials listed (Table 4). The register was initially
launched to list randomized trials but is now open to all
study designs. Over 95% of the content still deals with
interventional studies and randomized trials.
 In line with ICMJE guidelines, the aim is to make sure
that trials are publicly registered prospectively, i.e. before
the ﬁrst participants are enrolled and randomized. For
the ISRCTN register, a trial is registered retrospectively
if the application is made before the anticipated start date
of the trial (minus a grace period of 30 days). In practice,
the majority of trials are still registered retrospectively,
although the percentage of prospective registration has
increased signiﬁcantly over the years (Table 5). The IS-
RCTN register accepts retrospective registration, whether
the trial is ongoing or completed at time of registration,
because an inclusion in a database such as the ISRCTN
registerisstillconsideredabetteroptionthannoinclusion
at all. Furthermore, ICMJE member journals do not yet
fully adhere to the ICMJE registration policy, and allow
retrospective registration to take place (9).
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Table 3 Top 20 countries in the ISRCTN
Country 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
UK 145 183 228 677 923 675 552 507 372 378 608
Netherlands 3 4 17 356 348 239 33 37 50
Germany 3 15 15 76 73 97 92 83 68
Canada 1 9 6 16 138 45 54 55 29 27
Switzerland 2 3 28 45 44 39 33 27 35
USA 9 10 16 50 44 20 32 24 27
Spain 3 13 23 19 26 30 40
A u s t r a l i a 1 4 81 33 61 31 71 2 81 7
I t a l y 31699 1 8 1 8 2 9 2 9
F r a n c e 1118 1 8 1 8 2 9 1 6 2 5
Sweden 1 1 4 12 22 30 23 21
Belgium 4 2 8 9 10 22 13 15
Brazil 1 1 2 11 9 20 8 15
China 3 8 15 14 8 17
Finland 1 2 3 11 11 9 10 13
D e n m a r k 2 347 1 047 1 7
India 1 1 9 9 14 12 1 9
Ireland 1 1 61 21 41 6
N o r w a y 11 47 1 5813
S Korea 61 0 81 0
Others 0 2 30 2 17 49 60 74 65 82 84
Total 145 187 302 729 1065 1493 1304 1220 908 836 1146
Trial registration in the United
Kingdom and overall challenges
There is no legal requirement to publicly register clinical tri-
als in the UK. However, a number of organizations will col-
lect different sets of information and any clinical researcher
must follow strict procedures for the ethical review of their
trial protocol (10). The Chief Investigator must apply for
ethics approval. This should be made via the Integrated Re-
search Application System (IRAS) which provides a ‘one-
stop shop’ showing all the relevant permissions and ap-
provalsneeded,includingtheclinicaltrialauthorizationtobe
Table 4 Numbers of interventional trials and observational studies in
ISRCTN
Year Intervention trials Observational studies
2000 145 0
2001 187 0
2002 302 0
2003 727 2
2004 1062 3
2005 1491 2
2006 1275 29
2007 1175 45
2008 861 47
2009 791 45
2010 1037 109
submitted to the Medicines and Healthcare products Regula-
tory Authority (MHRA) (11). Research studies are reviewed
byNHSResearchEthicsCommittees(RECs)establishedun-
der policy from the relevant Health Departments in each of
the four UK nations. The National Research Ethics Service
(NRES) is the administrative body responsible for providing
advice, assistance and operational support to NHS RECs for
the whole of the UK (12).
The ISRCTN register is in regular contact with both the
IRAS and the NRES organizations to ensure that systems
whose aim is to facilitate the running of clinical trials in the
UK also promote public registration and include trial IDs in
Table 5 Numbers of trials registered prospectively and retrospec-
tively in the ISRCTN
Year Prospective Retrospective
2000 21 124
2001 37 150
2002 47 255
2003 51 678
2004 99 966
2005 247 1,246
2006 385 919
2007 450 770
2008 453 455
2009 440 396
2010 433 713
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their datasets and to discuss the feasibility of regular data
exchanges.
Increased participation in trials is very much supported by
the UK government (13). In 2010, the decision was taken to
develop a UK Clinical Trials Gateway (UKCTG) aiming to
provide a list of the trials that have enrolled or are enrolling
UK participants, in a single environment (14). The sources
used are the UK-based international ISRCTN register and
the US-based ClinicalTrials.gov register (15). CCT provided
data and consulting services to the Department of Health to
ensurethelaunchoftheUKCTGwebsiteinMarch2011.The
existenceoftheUKCTGhasbeennotedintheGovernment’s
Budget for 2011 (16).
All European trial regulatory agencies contribute to the
European EudraCT database. In March 2011, the European
Medicines Agency (EMA) launched a public view of this
data as the EU-Clinical Trials Register (17).
Some of the challenges that remain include:
 Continue to promote prospective registration. The focus
should be to promote registration with health research
funding bodies. There have been marketing efforts in the
past and a lot will depend on the overall position of those
organizations regarding mandating free access to ongoing
and published research.
 Buildontheincreasedavailabilityofinformationonphar-
maceutical industry trials through the recently launched
European Register.
 Manage expectations in terms of completeness and qual-
ity of data, which is a resource intensive activity for
registers (18).
 Encourage trialists to record complete and high quality
data in trial registration databases, such as methodologic
information, so that trials can be critically appraised (19).
 Ensure that more potential participants are made aware of
research that is relevant to them by making sure that clini-
cal trial information is presented in lay-friendly terms, an
aspect considered key to the success of the UKCTG. Ac-
knowledging that the scientiﬁc format of trial information
might not facilitate increased participation, the ISRCTN
register has also been working on introducing a new ﬁeld
to allow researchers to provide a lay summary of their
trial.
 Strengthen the link between a registered trial and its re-
sulting publications. Trial registration databases in part-
nership with journals have an important role to play in
increasing transparency in trial reporting and reducing
reporting bias (for a review see (20)), to improve the
medical evidence base and, ultimately, patient care. By
improving links between trial registers and resulting pub-
lications, readers and systematic reviewers of the medi-
cal evidence will have better access to information that is
usedtoinformpracticedecisions.Electronicjournalswith
unlimitedspacealsohavetheopportunitytoreportallsci-
entiﬁcally sound research, regardless of the outcome of
the trial. BioMed Central has put into practice one of
the original aims of the ISRCTN scheme by quoting trial
IDs on an increasing number of articles (over 200 papers
published quoting the ISRCTN trial ID, over 70 with the
ClinicalTrials.govtrialID).BioMedCentralisalsotaking
thisfurtherandrecentlylauncheditsthreadedpublications
concept (21), in which the ISRCTN register provides the
ﬁrst step in a sequence of ‘threaded’ electronic publica-
tions (22) relating to a particular trial of a particular treat-
ment. Any publications – protocols, results, secondary
analysis, case reports and datasets – that include the IS-
RCTN Trial ID in the abstract are hyperlinked back to
the trial database, and the same system operates for the
three other largest global trial databases, including Clin-
icalTrials.gov. BioMed Central has also been promoting
and providing guidelines for the principle of raw clinical
data sharing and publication, which represents maximum
transparency in clinical research, as data are available for
alternativeanalyses,externalscrutinyandforthesimpliﬁ-
cation and enhancement of systematic reviews and meta-
analyses(23).Thisfocushashelpedfacilitatethepublica-
tion, as a stand-alone peer-reviewed article in the journal
Trials, the individual participant data (more than 19,000
patients) from one of the largest trials ever conducted in
acute stroke (24). As clinical data sharing and publication
becomes more common and with effective links between
journal publications and trial registration databases, there
are real opportunities to enhance the medical literature.
Conclusion
Althoughtherearemanyexpectationsforthenumber,quality
and accessibility of clinical trials, the volume of information
that is publicly available has evolved dramatically over the
pastdecade.Progresshasbeenmadeindeﬁningandapplying
standards.Sciencepublishershavearoletoplayinrequesting
evidence of prospective registration and in facilitating the
sharing and publication of all elements of trials, from study
registration through to the raw data.
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